EVMN

+ Watchlist + Portfolio

Evommune, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $15.01
52-Week Range: $10.47 – $33.20
Market Cap: $492.48M
P/E (TTM): —
EPS (TTM): -11.82
Dividend Yield: —

Advanced Metrics

Price/Book: 1.77
PEG Ratio: —
Return on Equity: -52.11%
Return on Assets: -31.99%
Gross Margin: 100.00%
Operating Margin: -1018.94%
Profit Margin: 0.00%
Current Ratio: 11.68
Debt/Equity: 0.03
Total Debt: $8.63M
Free Cash Flow: $-39.13M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $300.32M

EVMN Income statement, annual periods, in USD
USD	FY2024	FY2025
Revenue	—	$13.00M
Research & Development	—	$74.04M
Selling, General & Admin	—	$20.03M
Operating Expenses	—	$94.07M
Operating Income	—	-$81.07M
EBITDA	—	-$79.68M
Pretax Income	—	-$68.87M
Net Income	—	-$68.87M
Diluted EPS	-4.27	-11.22
Diluted Shares	16.00M	6.14M

EVMN Balance Sheet statement, annual periods, in USD
USD	FY2024	FY2025
Cash & Equivalents	—	$44.06M
Current Assets	—	$153.48M
Total Assets	—	$224.95M
Current Liabilities	—	$17.91M
Total Debt	$1.02M	$1.71M
Total Liabilities	—	$19.38M
Retained Earnings	—	-$221.09M
Shareholders' Equity	—	$205.57M
Working Capital	—	$135.57M

EVMN Income statement, quarterly periods, in USD
USD	Q4 2024	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$10.00M	$0.00	$0.00
Research & Development	$17.83M	$19.64M	$20.40M	$17.32M
Selling, General & Admin	$3.62M	$3.69M	$9.31M	$6.63M
Operating Expenses	$21.45M	$23.33M	$29.72M	$23.95M
Operating Income	-$21.45M	-$13.33M	-$29.72M	-$23.95M
EBITDA	-$21.09M	-$13.02M	-$29.39M	-$23.61M
Pretax Income	-$20.73M	-$12.47M	-$28.27M	-$21.67M
Net Income	-$20.73M	-$12.47M	-$28.27M	-$21.67M
Diluted EPS	—	-0.41	-1.43	-0.64
Diluted Shares	—	30.08M	19.78M	33.67M

EVMN Balance Sheet statement, quarterly periods, in USD
USD	Q4 2024	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$16.25M	$26.82M	$44.06M	$48.32M
Current Assets	$73.99M	$81.94M	$153.48M	$215.85M
Total Assets	$76.06M	$84.54M	$224.95M	$322.45M
Current Liabilities	$27.98M	$10.42M	$17.91M	$10.60M
Total Debt	$1.02M	$160.00K	$1.71M	$8.55M
Total Liabilities	$220.29M	$267.68M	$19.38M	$17.90M
Retained Earnings	-$152.22M	-$192.82M	-$221.09M	-$242.76M
Shareholders' Equity	-$144.24M	-$183.14M	$205.57M	$304.56M
Working Capital	$46.01M	$71.53M	$135.57M	$205.25M

Market Snapshot

About

Evommune, Inc. is a clinical-stage biopharmaceutical company focused on developing oral therapies for autoimmune and inflammatory diseases. The company's lead product candidate is designed to modulate immune responses through a novel mechanism of action targeting specific pathways involved in autoimmune conditions. Evommune's approach aims to provide effective treatment while minimizing the immunosuppression and safety concerns associated with existing therapies. The company is advancing its pipeline through clinical development with a focus on conditions with significant unmet medical needs. Evommune represents an innovative approach to treating autoimmune diseases through targeted oral immunomodulation.